Navigation

Clinical audit

NICE produces clinical audit tools for local clinical audit to improve care, containing clinical audit standards based on NICE guidance.

The most recent documents are Excel based and also contain:

  • a data collection sheet
  • a clinical audit report that provides basic information about the audit and automatically displays the audit results
  • an action plan template
  • an appendix containing a printable data collection form.

Previous versions of the Clinical audit tools produced by NICE to accompany guidance were called Audit support or Audit criteria.

Access all the clinical audit documents from the list below. The most recent clinical audit tools can be found at the bottom of the list.

For quick access to some recent examples of the clinical audit tools we produce, please follow the links below:

Clinical audit tools for CG156 Fertility

Clinical audit tools for CG157 Hyperphosphataemia in chronic kidney disease

Clinical audit tool for CG158 Conduct disorders in children and young people

Tell us what you think

We want to hear what you think of clinical audit and your experiences of using them.

Details of some of the work we have done to improve our audit tools can be found in the NICE clinical audit survey report 2011.

External Reference Group

If you are a clinical audit specialist or healthcare professional who would be prepared to help us review the clinical audit tools, please apply to join our 'Audit Panel'.

Ref Title Setting
TA167 Abdominal aortic aneurysm - endovascular stent-grafts: audit support
TA182 Acute coronary syndrome - prasugrel: audit support
TA236 Acute coronary syndromes - ticagrelor: clinical audit tool General
CG169 Acute kidney injury: clinical audit tools General
CG50 Acutely ill patients in hospital: audit criteria
CG141 Acute upper GI bleeding: clinical audit tools General
CG115 Alcohol dependence and harmful alcohol use: audit support General
CG100 Alcohol-use disorders: physical complications: audit support General
PH24 Alcohol-use disorders - preventing harmful drinking: Audit support - Clinical criteria General
IPG257 Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus: audit support
TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: audit support General
IPG192 Amnioinfusion for oligohydramnios during pregnancy: Audit criteria
TA142 Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin: audit support
CG134 Anaphylaxis: clinical audit tool General
TA143 Ankylosing spondylitis - adalimumab, etanercept and infliximab: audit support General
TA233 Ankylosing spondylitis - golimumab: clinical audit tool General
CG45 Antenatal and postnatal mental health: audit criteria
CG62 Antenatal care: audit support
CG149 Antibiotics for early-onset neonatal infection: clinical audit tools General
CG77 Antisocial personality disorder: audit support General
CG113 Anxiety: audit support General
TA238 Arthritis (juvenile idiopathic, systemic) - tocilizumab: clinical audit tool General
IPG474 Arthroscopic trochleoplasty for patellar instability: clinical audit tool General
TA138 Asthma (in adults) - corticosteroids: audit support General
TA131 Asthma (in children) - corticosteroids: audit criteria
CG57 Atopic eczema in children: audit support
TA256 Atrial fibrillation (stroke prevention) - rivaroxaban: clinical audit tool General
TA249 Atrial fibrillation - dabigatran etexilate: clinical audit tool General
TA197 Atrial fibrillation - dronedarone: audit support
CG72 Attention deficit hyperactivity disorder (ADHD): audit support tools General
CG142 Autism in adults: clinical audit tools General
CG128 Autism in children and young people: clinical audit tool General
CG170 Autism - management of autism in children and young people: clinical audit tool General
IPG437 Autologous blood injection for plantar fasciopathy: clincal audit tool General
IPG438 Autologous blood injection for tendinopathy: clinical audit tool General
IPG274 Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy: audit support
CG102 Bacterial meningitis and meningococcal septicaemia: audit support General
TA263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer: advanced breast cancer technology appraisals clinical audit tool General
TA265 Bone metastases from solid tumours - denosumab: clinical audit tool General
CG78 Borderline personality disorder (BPD): audit support
CG81 Breast cancer (advanced): audit support
TA250 Breast cancer (advanced) - eribulin: multiple guidance audit tool General
TA109 Breast cancer (early) - docetaxel: audit criteria
TA109 Breast cancer (early) - docetaxel: multiple guidance audit tool General
TA112 Breast cancer (early) - hormonal treatments: audit criteria
TA112 Breast cancer (early) - hormonal treatments: multiple guidance audit tool General
TA108 Breast cancer (early) - paclitaxel: multiple guidance audit tool General
TA107 Breast cancer (early) - trastuzumab: audit criteria
TA107 Breast cancer (early) - trastuzumab: multiple guidance audit tool General
CG80 Breast cancer (early & locally advanced): audit support General
TA239 Breast cancer (metastatic) - fulvestrant: advanced breast cancer technology appraisals clinical audit tool General
TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Advanced Breast Cancer technology appraisals clinical audit tool General
TA214 Breast cancer - bevacizumab (in combination with a taxane): advanced breast cancer technology appraisals clinical audit tool General
TA116 Breast cancer - gemcitabine: advanced breast cancer technology appraisals clinical audit tool General
TA34 Breast cancer - trastuzumab: advanced breast cancer technology appraisals clinical audit tool General
PH1 Brief interventions and referral for smoking cessation: audit criteria
CG132 Caesarean section: clinical audit tools General
TA183 Cervical cancer (recurrent) - topotecan: audit support
CG95 Chest pain of recent onset: audit support
CG53 Chronic fatigue syndrome / Myalgic encephalomyelitis: audit criteria
CG108 Chronic heart failure: audit support
CG73 Chronic kidney disease: audit support General
TA202 Chronic lymphocytic leukaemia - ofatumumab: audit support General
CG101 Chronic obstructive pulmonary disease (update): audit support General
IPG410 Closure of anorectal fistula using a suturable bioprosthetic plug: clinical audit tool General
CG86 Coeliac disease: audit support
CG118 Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas: audit support General
CG131 Colorectal cancer: clinical audit tools General
TA176 Colorectal cancer (first line) - cetuximab: biological agents for metastatic colorectal cancer - clinical audit tool General
TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): biological agents for metastatic colorectal cancer - clinical audit tool General
TA212 Colorectal cancer (metastatic) - bevacizumab: biological agents for metastatic colorectal cancer - clinical audit tool General
TA118 Colorectal cancer (metastatic) - bevacizumab and cetuximab: biological agents for metastatic colorectal cancer - clinical audit tool General
TA61 Colorectal cancer - capecitabine and tegafur uracil: chemotherapy for advanced and metastatic colorectal cancer - clinical audit tool General
IPG297 Combined bony and soft tissue reconstruction for hip joint stabilisation in proximal focal femoral deficiency (PFFD): audit support
CG158 Conduct disorders in children and young people: clinical audit tool General
CG99 Constipation in children and young people: audit support
IPG455 Corneal inlay implantation for correction of Presbyopia: clinical audit tool General
TA152 Coronary artery disease - drug-eluting stents: audit support
CG83 Critical illness rehabilitation: audit support
CG152 Crohn's disease: clinical audit tool General
TA187 Crohn's disease - infliximab (review) and adalimumab (review of TA40): audit support
IPG369 Cryotherapy for the treatment of liver metastases: audit support General
IPG331 Cytoreduction surgery followed by hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis: audit support
IPG381 Deep brain stimulation for intractable trigeminal autonomic cephalalgias: audit support General
IPG416 Deep brain stimulation for refractory epilepsy: clinical audit tool General
IPG439 Deep dermal injection of non-absorbable gel polymer for HIV-related facial lipoatrophy: clinical audit tool General
CG103 Delirium: audit support
CG42 Dementia: clinical audit tools General
CG90 Depression in adults (update): audit support
CG91 Depression with a chronic physical health problem: audit support
CG63 Diabetes in pregnancy: audit support
TA151 Diabetes - insulin pump therapy: audit support
CG119 Diabetic foot problems - inpatient management: audit support General
CG84 Diarrhoea and vomiting in children under 5: audit support
IPG270 Direct skeletal fixation of prosthethes using intraosseous transcutaneous implants: audit support
CG93 Donor breast milk banks: audit support
TA114 Drug misuse - methadone and buprenorphine: audit criteria
TA115 Drug misuse - naltrexone: audit criteria
CG154 Ectopic pregnancy and miscarriage: clinical audit tools General
TA177 Eczema (chronic) - alitretinoin: audit support
IPG324 Electrocautery cutting balloon treatment for pelviureteric junction obstruction: audit support
IPG404 Endoluminal gastroplication for gastro-oesophageal reflux disease: clinical audit tool General
IPG222 Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease: Audit criteria
IPG425 Endoscopic balloon dilatation for subglottic or tracheal stenosis: clinical audit tool General
IPG359 Endoscopic mucosal resection and endoscopic submucosal dissection of non-ampullary duodenal lesions: audit support General
IPG398 Endoscopic radical inguinal lymphadenectomy: clinical audit tool General
IPG461 Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease: clinical audit tool General
IPG393 Endoscopic radiofrequency therapy of the anal sphincter for faecal incontinence: clinical audit tool General
IPG355 Endoscopic submucosal dissection (ESD) of oesophageal dysplasia and neoplasia: audit support General
IPG360 Endoscopic submucosal dissection of gastric lesions: audit support General
IPG335 Endoscopic submucosal dissection of lower gastrointestinal lesions: audit support
IPG335 Endoscopic submucosal dissection of lower gastrointestinal lesions: electronic clinical audit tool General
IPG411 Endoscopic transluminal pancreatic necrosectomy: clinical audit tool General
IPG390 Endovascular stent-grafting of popliteal aneurysms: clinical audit tool General
IPG435 Endovenous mechanochemical ablation for varicose veins: clinical audit tool General
CG137 Epilepsy: clinical audit tools General
IPG344 Epithelial radiofrequency ablation for Barrett's oesophagus: audit support
IPG394 External aortic root support in Marfan syndrome: clinical audit tool General
IPG316 Extracorporeal albumin dialysis for acute liver failure: audit support
IPG428 Extracorporeal membrane carbon dioxide removal: audit support General
IPG312 Extracorporeal shockwave therapy for refractory Achilles tendinopathy: audit support
IPG376 Extracorporeal shockwave therapy for refractory greater trochanteric pain syndrome: audit support General
IPG311 Extracorporeal shockwave therapy for refractory plantar fasciitis: audit support
IPG313 Extracorporeal shockwave therapy for refractory tennis elbow: audit support
IPG348 Extracranial to intracranial bypass for intracranial atherosclerosis: audit support
IPG298 Ex-vivo hepatic resection and reimplantation for liver cancer: audit support
CG49 Faecal incontinence: audit criteria
CG161 Falls: clinical audit tools General
CG71 Familial hypercholesterolaemia: audit support
CG156 Fertility: clinical audit tools General
IPG205 Fetal cystoscopy for diagnosis and treatment of lower urinary outflow tract obstruction: Audit criteria
IPG202 Fetal vesico-amniotic shunt for lower urinary tract outflow obstruction: Audit criteria
CG160 Feverish illness in children: clinical audit tools General
IPG423 Focal therapy using cryoablation for localised stage prostate cancer: clinical audit tool General
IPG424 Focal therapy using high-intensity focused ultrasound (HIFU) for localised prostate cancer: clinical audit tool General
CG116 Food allergy in children and young people: audit support General
PH2 Four commonly used methods to increase physical activity: audit criteria
TA191 Gastric cancer (advanced) - capecitabine: audit support General
TA208 Gastric cancer (HER2-positive metatastic) - trastuzumab: audit support General
TA209 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib: audit support General
TA196 Gastrointestinal stromal tumours - imatinib (adjuvant): audit support
TA179 Gastrointestinal stromal tumours - sunitinib: audit support
CG85 Glaucoma: audit support
TA121 Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: audit criteria
TA203 GLP-1 agonists for the treatment of type 2 diabetes: clinical audit tool General
TA248 GLP-1 agonists for the treatment of type 2 diabetes: clinical audit tool General
TA128 Haemorrhoid - stapled haemorroidopexy: audit criteria
CG150 Headaches: clinical audit tool General
TA172 Head and neck cancer (squamous cell carcinoma) - cetuximab: audit support
CG176 Head injury: clinical audit tool General
TA166 Hearing impairment - cochlear implants: audit support
TA120 Heart failure - cardiac resynchronisation: audit criteria
CG44 Heavy menstrual bleeding: audit criteria
CG165 Hepatitis B: clinical audit tools General
TA153 Hepatitis B - entecavir: audit support
TA154 Hepatitis B - telbivudine: audit support
TA173 Hepatitis B - tenofovir disoproxil fumarate: audit support
TA253 Hepatitis C (genotype 1) - boceprevir: clinical audit tool General
TA252 Hepatitis C (genotype 1) - telaprevir: clinical audit tool General
TA200 Hepatitis C - peginterferon alfa and ribavirin: audit support
TA189 Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line): audit support
CG124 Hip fracture: clinical audit tools General
TA188 Human growth hormone (somatropin) for the treatment of growth failure in children: audit support
TA132 Hypercholesterolaemia - ezetimibe: audit criteria General
CG130 Hyperglycaemia in acute coronary syndromes: clinical audit tool General
TA117 Hyperparathyroidism - cinacalcet: audit criteria General
CG157 Hyperphosphataemia in chronic kidney disease: clinical audit tools General
CG127 Hypertension: clinical audit tool General
CG107 Hypertension in pregnancy: audit support
TA164 Hyperuricaemia - febuxostat: audit support
IPG486 Hysteroscopic morcellation of uterine fibroids: clinical audit tool General
CG163 Idiopathic pulmonary fibrosis: clinical audit tool General
IPG308 Image-guided radiofrequency excision biopsy of breast lesions: audit support
IPG209 Implantation of accommodating intraocular lenses during cataract surgery: Audit criteria
IPG272 Implantation of lens systems for advanced age-related macular degeneration: audit support
IPG422 Incisionless otoplasty: clinical audit tool General
PH33 Increasing the uptake of HIV testing among black Africans in England: clinical audit tools General
PH34 Increasing the uptake of HIV testing among men who have sex with men: clinical audit tools General
CG70 Induction of labour: audit support
CG139 Infection control: clinical audit tools General
TA158 Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: audit support
TA168 Influenza - zanamivir, amantadine and oseltamivir (review): audit support
IPG210 Injectable bulking agents for faecal incontinence: Audit criteria
IPG463 Insertion and use of implantable pulmonary artery pressure monitors in chronic heart failure: clinical audit tool General
IPG465 Insertion of endobronchial valves for lung volume reduction in emphysema: clincal audit tool General
IPG448 Insertion of endobronchial valves for treatment of persistent air leaks: clinical audit tool General
IPG190 Insertion of pleuro-amniotic shunt for fetal pleural effusion - audit criteria
IPG259 Interstitial photodynamic therapy for malignant parotid tumours: Audit support
IPG197 Intramedullary distraction for lower limb lengthening: Audit criteria
IPG307 Intramuscular diaphragm stimulation for ventilator dependent chronic respiratory failure due to neurological disease: audit support
CG55 Intrapartum care: audit criteria
CG174 Intravenous fluid therapy in adults in hospital: clinical audit tool General
CG61 Irritable bowel syndrome: audit support
IPG228 Laparoscopic cerclage for prevention of recurrent pregnancy loss due to cervical incompetence: audit criteria
IPG431 Laparoscopic insertion of a magnetic bead band for gastro-oesophageal reflux disease: clinical audit tool General
IPG252 Laser-assisted non-occlusive cerebral vascular anastomosis without temporary arterial occlusion: Audit criteria
IPG321 Lateral (including extreme, extra and direct lateral) interbody fusion in the lumbar spine: audit support
TA174 Leukaemia (chronic lymphocytic, first line) - rituximab: audit support
TA193 Leukaemia (chronic lymphocytic, relapsed) - rituximab: audit support
TA241 Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant): clinical audit tool General
TA119 Leukaemia (lymphocytic) - fludarabine: Audit criteria
IPG339 Limited macular translocation for wet age-related macular degeneration: audit support
CG67 Lipid modification: audit support General
IPG251 Liposuction for chronic lymphoedema: Audit criteria
CG88 Low back pain: audit support
IPG219 Lower limb deep vein valve reconstruction for chronic deep venous incompetence: Audit criteria
CG147 Lower limb peripheral arterial disease: clinical audit tools General
CG97 Lower urinary tract symptoms: audit support statement General
CG121 Lung cancer: clincal audit tools General
TA227 Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): clinical audit tool General
TA227 Lung cancer (non small cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): mutliple guidance audit tool General
TA258 Lung cancer (non small cell, EGFR-TK mutation positive) - eroltinib (1st line): clinical audit tool General
TA192 Lung cancer (non-small-cell, first line) - gefitinib: audit support General
TA192 Lung cancer (non small cell, first line) - gefitinib: multiple guidance audit tool General
TA181 Lung cancer (non-small cell, first line treatment) - pemetrexed: audit support
TA181 Lung cancer (non small cell, first line treatment) - pemetrexed: multiple guidance audit tool General
TA162 Lung cancer (non-small-cell) - erlotinib: audit support
TA162 Lung cancer (non small cell) - erlotinib: multiple guidance audit tool General
TA124 Lung cancer (non small cell) - pemetrexed: multiple guidance audit tool General
TA190 Lung cancer (non small cell) - pemetrexed (maintenance): multiple guidance audit tool General
TA190 lung cancer (non-small-cell) - permetrexed (maintenance): audit support
TA184 Lung cancer (small-cell) - topotecan: audit support
TA137 Lymphoma (follicular non-Hodgkin's) - rituximab: Audit support
TA68 Macular degeneration (age-related) - photodynamic therapy: clinical audit tool General
TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib: clinical audit tool General
TA294 Macular degeneration (wet age-related) - aflibercept: clinical audit tool General
IPG340 Macular translocation with 360° retinotomy for wet age related macular degeneration: audit support
IPG413 Magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids: audit criteria
PH11 Maternal and child nutrition: audit support
CG76 Medicines adherence: audit support
PH16 Mental wellbeing and older people: audit support
TA135 Mesothelioma - pemetrexed disodium: audit criteria
CG104 Metastatic malignant disease of unknown primary origin: audit support
CG75 Metastatic spinal cord compression: audit support
IPG426 Micropressure therapy for refractory Ménière's disease: clinical audit tool General
IPG406 Microwave ablation for the treatment of liver metastases: clincal audit tool General
IPG238 Mini/micro screw implantation for orthodontic anchorage: audit criteria
CG51 Misuse of drugs and other substances: audit criteria
CG105 Motor neurone disease - non-invasive ventilation: audit support
TA228 Multiple myeloma (first line) - bortezomib and thalidomide: Clinical audit tool General
TA171 Multiple myeloma - audit support
TA129 Multiple myeloma - bortezomib: audit criteria
CG129 Multiple pregnancy: clincal audit tools General
TA254 Multiple sclerosis (relapsing-remitting) - fingolimod: clinical audit tool General
TA127 Multiple sclerosis - natalizumab: audit criteria
TA218 Myelodysplastic syndromes - azacitidine: audit support General
TA230 Myocardial infarction (persistent ST-segment elevation) - bivalirudin: clinical audit tool General
CG172 Myocardial infarction - secondary prevention: clinical audit tool General
CG167 Myocardial infarction with ST-segment elevation: clinical audit tool General
CG98 Neonatal jaundice: audit support (MS Word format) General
CG151 Neutropenic sepsis: clinical audit tools General
CG111 Nocturnal enuresis - the management of bedwetting in children and young people: audit support General
CG43 Obesity: audit criteria
CG140 Opioids in palliative care: clinical audit tools General
TA165 Organ preservation (renal) - machine perfusion and static storage: audit support
CG146 Osteoporosis fragility fracture: clinical audit tool General
TA160 Osteoporosis - primary prevention: audit support
TA161 Osteoporosis - secondary prevention including strontium ranelate: audit support
TA204 Osteoporotic fractures - denosumab: audit support General
CG122 Ovarian cancer: audit tools General
TA159 Pain (chronic neuropathic or ischaemic) - spinal cord stimulation: audit support
IPG430 Partial replacement of the meniscus of the knee using a biodegradable scaffold: clinical audit tool General
IPG196 Patient safety and reduction of risk of transmission of Creutzfeldt-Jakob disease (CJD) via interventional procedures: Audit criteria
TA124 Pemetrexed for the treatment of non-small-cell lung cancer: audit criteria
IPG380 Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices: audit support General
IPG303 Percutaneous endoscopic laser cervical discectomy: audit support
IPG300 Percutaneous endoscopic laser lumbar discectomy: audit support
IPG319 Percutaneous intradiscal electrothermal therapy for low back pain: audit support
IPG395 Percutaneous tibial nerve stimulation (PTNS) for faecal incontinence: clinical audit tool General
CG65 Perioperative hypothermia (inadvertent): audit support
TA223 Peripheral arterial disease - cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate: clinical audit tool General
IPG466 Photochemical corneal collagen cross linkage using riboflavin and ultraviolet A for keratoconus and keratectasia: clinical audit tool General
IPG350 Photodynamic therapy for Barrett's oesophagus: audit support
IPG200 Photo-dynamic therapy for early oesophageal cancer: Audit criteria
TA156 Pregnancy (rhesus negative women) - routine anti-D (review): audit support
IPG201 Preoperative high dose rate brachytherapy for rectal cancer: Audit criteria
PH3 Prevention of sexually transmitted infections and under 18 conceptions: audit criteria
PH17 Promoting physical activity for children and young people: audit support General
CG64 Prophylaxis against infective endocarditis: audit support
CG175 Prostate cancer: clinical audit tool General
TA101 Prostate cancer (hormone-refractory) - docetaxel: multiple guidance audit tool General
TA259 Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): multiple guidance audit tool General
TA255 Prostate cancer - cabazitaxel: multiple guidance audit tool General
TA211 Prucalopride for chronic constipation in women: audit support General
TA211 Prucalopride for chronic constipation in women: electronic audit tool General
CG153 Psoriasis: clinical audit tools General
TA146 Psoriasis - adalimumab: audit support
TA134 Psoriasis - inflixamib: Audit criteria
TA180 Psoriasis - ustekinumab: audit support
TA199 Psoriatic arthritis - etanercept, infliximab and adalimumab: audit support
TA220 Psoriatic arthritis - golimumab: clinical audit tool General
CG155 Psychosis and schizophrenia in children and young people: clinical audit tools General
CG120 Psychosis with coexisting substance misuse: clinical audit tool General
IPG368 Radiation therapy for early Dupuytren's disease: audit support General
PH21 Reducing the differences in the uptake of immunisations: audit tools General
TA178 Renal cell carcinoma: audit support
TA215 Renal cell carcinoma (first line metastatic) - pazopanib: audit statement General
TA169 Renal cell carcinoma - sunitinib: audit criteria
CG69 Respiratory tract infections: audit support
CG79 Rheumatoid arthritis: audit support
TA130 Rheumatoid arthritis - adalimumab, etanercept and infliximab: audit support
TA186 Rheumatoid arthritis - certolizumab pegol: audit support
TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: audit support
TA213 Schizophrenia - aripiprazole: audit support Mental health trusts
CG112 Sedation in children and young people: audit statement General
CG133 Self-harm (longer term management): clinical audit tools General
IPG199 Septostomy with our without amnioreduction for the treatment of twin-to-twin transfusion syndrome: Audit Criteria
CG136 Service user experience in adult mental health: clinical audit tools General
CG143 Sickle cell acute painful episode: clinical audit tool General
IPG346 Single-incision laparoscopic cholecystectomy: audit support
IPG414 Single-port laparoscopic nephrectomy: clinical audit tool General
IPG305 Sinus tarsi implant insertion for mobile flatfoot: audit support
TA139 Sleep apnoea - continuous positive airway pressure (CPAP): audit support
PH39 Smokeless tobacco cessation - South Asian communities: clinical audit tool General
PH10 Smoking cessation services: audit support
Smoking cessation - varenicline: Audit criteria
TA123 Smoking cessation - varenicline: audit criteria
CG159 Social anxiety disorder: clinical audit tool General
TA185 Soft tissue sarcoma - trabectedin: audit support
CG145 Spasticity in children and young people: clinical audit tools General
CG126 Stable angina: clinical audit tool General
CG68 Stroke: audit support
TA264 Stroke (acute, ischaemic) - alteplase: clinical audit tool General
TA275 Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban: clinical audit tool General
TA136 Structural neuroimaging in first-episode psychosis: audit support
IPG332 Surgical correction of hallux valgus using minimal access techniques: audit support
CG60 Surgical management of OME: audit support
IPG267 Surgical repair of vaginal wall prolapse using mesh: audit support
CG74 Surgical site infection: audit support
PSG001 Technical patient safety solutions for medicines reconciliation on admission of adults to hospital: Audit Tool
PSG002 Technical patient safety solutions for prevention of ventilator-associated pneumonia in adults: audit support
IPG299 Tenotomy of horizontal eye muscles for nystagmus: audit support
IPG333 Therapeutic endoscopic division of epidural adhesions: audit support
IPG243 Thoracoscopic aortopexy for severe primary tracheomalacia: Audit criteria
IPG247 Thoracoscopic excision of mediastinal parathyroid tumours: Audit criteria
IPG400 Thoracoscopic exclusion of the left atrial appendage in atrial fibrillation (with or without other cardiac surgery) for the prevention of thromboembolism: clinical audit tool General
TA293 Thrombocytopenic purpura - eltrombopag: clinical audit tool General
TA221 Thrombocytopenic purpura - romiplostim: clinical audit tool General
TA221 Thrombocytopenic purpura - romiplostim: clinical audit tool General
IPG216 Tissue-cultured limbal stem cell allograft transplantation: clinical audit tool General
IPG329 Total prosthetic replacement of the temporomandibular joint: audit support
IPG271 Total wrist replacement: audit support
IPG396 Trabecular stent bypass micro-surgery for open angle glaucoma: clinical audit tool General
IPG276 Transabdominal artificial bowel sphincter implantation for faecal incontinence: audit support
IPG387 Transaxial interbody lumbosacral fusion: audit support tool General
IPG477 Transcranial magnetic stimulation for treating and preventing migraine: clinical audit tool General
CG109 Transient loss of consciousness in adults and young people: audit support
IPG364 Transperineal template biopsy of the prostate: audit support General
CG117 Tuberculosis: audit support General
CG66 Type 2 diabetes: audit support
TA288 Type 2 diabetes - Dapagliflozin combination therapy: clinical audit tool General
CG87 Type 2 diabetes - newer agents (a partial update of CG66): audit support General
CG166 Ulcerative colitis: clinical audit tools General
TA163 Ulcerative colitis (acute exacerbations) - infliximab: audit support
TA140 Ulcerative colitis (subacute manifestations) - infliximab: audit support
CG94 Unstable angina and NSTEMI: audit support
CG148 Urinary incontinence in neurological disease: clinical audit tools General
CG171 Urinary incontinence in women: clinical audit tool General
CG54 Urinary tract infection in children: audit criteria
IPG330 Vagus nerve stimulation for treatment-resistant depression: audit support
CG168 Varicose veins in the legs: clinical audit tool General
TA210 Vascular disease - clopidogrel and dipyridamole (Review of TA90): audit support tool General
CG144 Venous thromboembolic diseases: clinical audit tools General
TA157 Venous thromboembolism - dabigatran: audit support
CG92 Venous thromboembolism - reducing the risk: audit support General
TA170 Venous thromboembolism - rivaroxaban: audit support
PH11 Vitamin D for children and pregnant and breastfeeding women audit tool General
CG62 Vitamin D for children and pregnant and breastfeeding women audit tool General
PH27 Weight management before, during and after pregnancy: audit support General
CG89 When to suspect child maltreatment: audit support
PH5 Workplace interventions to promote smoking cessation: audit criteria (for PCTs and their providers)

This page was last updated: 05 June 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.